| Immunohistochemical Study of C-erbB-2 and VEGF Expression in Non-Small Cell Lung Cancer. |
|
Jong Wook Shin, Kyung Won Ha, Jae Cheol Choi, Jae Yeol Kim, In Whon Park, Byoung Whui Choi, Jae Hyung Yoo |
1Department of Internal Medicine, Chung-Ang University, Seoul, Korea.
2Department of Pathology College of Medicine, Chung-Ang University, Seoul, Korea. jhyoo@cau.ac.kr |
|
|
| Abstract |
BACKGROUND
Mutated or deregulated expression of C-erbB-2 causes this gene to function as a potent oncogene. Vascular endothelial growth factor (VEGF) is a crucial angiogenic molecule in lung cancer. Both C-erbB-2 and VEGF can promote growth, proliferation and metastasis in non-small cell lung cancer (NSCLC). The purpose of this study was to investigate evaluate the relationship between the expressions of the C-erbB-2 and VEGF genes using immunohistochemistry. MATERIALS AND METHODS: Ninety-five patients with NSCLC were involved (60 squamous cell carcinoma and 35 adenocarcinoma). The formalin-fixed paraffin embedded specimens were immunohistochemically stained for C-erbB-2 and VEGF using the avidin-biotin complex method. RESULTS: Positive C-erbB-2 expression was observed more often in adenocarcinomas than squamous cell carcinomas (p<0.05). Although the immunohistochemical expressions of C-erbB-2 and VEGF in non-small-cell lung cancer showed increased tendencies at an advanced stage, the correlation between early and advanced cancers was insignificant. In adenocarcinomas, the expressions of VEGF and C-erbB-2 were significantly (p<0.05). CONCLUSION: The overexpression fo C-erbB-2 was significantly higher in adenocarcinomas than squamous cell carcinomas, and correlated with the expression of VEGF in adenocarcinomas of the lungs. |
| Key Words:
C-erbB-2, VEGF, Non-small-cell lung cancer |
|
PDF Links
Full text via DOI
Download Citation
